EU regulatory reforms aim to unlock medtech innovation

  • Home
  • Newsroom
  • EU regulatory reforms aim to unlock medtech innovation
EU regulatory reforms aim to unlock medtech innovation - Axcellant

EU regulatory reforms aim to unlock medtech innovation

  1. maj 30, 2025

The EU is moving forward with key upgrades to its medical device and diagnostics regulations, specifically under the Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR).

Following years of regulatory bottlenecks, these changes are especially relevant to developers of diagnostics and Software as a Medical Device (SaMD).

At Axcellant, we help companies navigate this evolving landscape through trial design, submissions, and implementation. Greater predictability and clarity in the system open the door to faster innovation — a goal we fully support.

See how we guide medtech and diagnostics teams across the EU regulatory landscape.

Resources

Axcellant at ICNC Berlin: Following the Future of Nuclear Cardiology – and helping bring it to clinical reality

The Axcellant team recently attended the International Conference on Nuclear Cardiology (ICNC) in Berlin – one of the most important…

Axcellant Establishes Advisory Board to Strengthen Clinical and Strategic Leadership

Axcellant is pleased to announce the formation of its Advisory Board - a group of distinguished experts in clinical science,…

One trial is no longer enough. Regulators on both sides of the Atlantic are building a new model of clinical evidence

The FDA and the European Commission are changing the rules of the game simultaneously. The shift is from a single…